Brokerages predict that Syros Pharmaceuticals Inc (NASDAQ:SYRS) will announce ($0.57) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Syros Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.75) and the highest is ($0.49). Syros Pharmaceuticals reported earnings per share of ($0.48) in the same quarter last year, which would indicate a negative year over year growth rate of 18.8%. The company is scheduled to announce its next earnings report on Thursday, May 9th.
On average, analysts expect that Syros Pharmaceuticals will report full year earnings of ($2.10) per share for the current year, with EPS estimates ranging from ($2.29) to ($1.95). For the next fiscal year, analysts forecast that the business will post earnings of ($2.14) per share, with EPS estimates ranging from ($2.41) to ($1.87). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Syros Pharmaceuticals.
Syros Pharmaceuticals (NASDAQ:SYRS) last posted its earnings results on Thursday, March 7th. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.49) by ($0.05). Syros Pharmaceuticals had a negative return on equity of 64.43% and a negative net margin of 3,038.00%. The business had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $0.40 million.
In other Syros Pharmaceuticals news, major shareholder Venture Fund Vii L.P. Arch sold 167,503 shares of Syros Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $7.83, for a total transaction of $1,311,548.49. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 27.80% of the company’s stock.
Hedge funds have recently modified their holdings of the business. Bank of America Corp DE lifted its stake in Syros Pharmaceuticals by 205.9% during the fourth quarter. Bank of America Corp DE now owns 17,400 shares of the company’s stock worth $98,000 after purchasing an additional 11,711 shares during the last quarter. MetLife Investment Advisors LLC lifted its stake in shares of Syros Pharmaceuticals by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 20,338 shares of the company’s stock valued at $242,000 after acquiring an additional 7,230 shares during the last quarter. Rhumbline Advisers lifted its stake in shares of Syros Pharmaceuticals by 51.4% in the 4th quarter. Rhumbline Advisers now owns 32,406 shares of the company’s stock valued at $181,000 after acquiring an additional 10,995 shares during the last quarter. Bank of New York Mellon Corp lifted its stake in shares of Syros Pharmaceuticals by 10.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 77,654 shares of the company’s stock valued at $925,000 after acquiring an additional 7,062 shares during the last quarter. Finally, Alps Advisors Inc. lifted its stake in shares of Syros Pharmaceuticals by 30.6% in the 4th quarter. Alps Advisors Inc. now owns 77,768 shares of the company’s stock valued at $433,000 after acquiring an additional 18,215 shares during the last quarter. 67.87% of the stock is owned by hedge funds and other institutional investors.
Syros Pharmaceuticals stock traded up $0.43 during midday trading on Monday, hitting $9.14. 72,180 shares of the company’s stock were exchanged, compared to its average volume of 160,537. Syros Pharmaceuticals has a 52-week low of $5.17 and a 52-week high of $13.86. The stock has a market cap of $285.40 million, a price-to-earnings ratio of -4.79 and a beta of 1.22.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Featured Story: What do investors mean by earnings per share?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.